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Chapter 10.     The Human Respiratory Microbiome: Implications and Impact 
  




Once considered a sterile site below the larynx, the tracheobronchial tree and parenchyma of 
the lungs are now known to harbor a rich diversity of microbial species including bacteria, 
viruses, fungi and archaea. Many of these organisms, particularly the viruses which comprise 
the human respiratory virome have not been identified, so their true role is unknown. It seems 
logical to conclude that a “healthy” respiratory microbiome exists which may be modified in 
disease states and perhaps by therapies such as antibiotics, antifungals and antiviral 
treatments. It is likely that there is a critical relationship or equilibrium between components of 
the microbiome until such time as perturbations occur which lead to a state of dysbiosis or an 
“unhealthy” microbiome. The act of lung transplantation provides an extreme change to an 
individual’s respiratory microbiome as, in effect, the donor respiratory microbiome is 
transplanted into the recipient. The mandatory ex vivo period of the donor lungs appears to 
be associated with blooms of resident viral species in particular. Subsequently, allograft injury, 
rejection and immune suppressive therapy all combine to create periods of dysbiosis which 
when combined with transient infections such as community acquired respiratory viruses may 
facilitate the development of chronic allograft dysfunction in predisposed individuals. As our 
understanding of the respiratory microbiome is rapidly expanding, based on the use of new 
generation sequencing tools in particular, it is to be hoped that insights gained into the subtle 
relationship between the microbiome and the lung allograft will facilitate improved outcomes 









The microbiome consists of all micro-organisms and their products that occupy surfaces within 
the human body. Each major compartment of the human body appears to have a unique 
microbiome with species which are specific for that environment. The microbiome 
encompasses bacteria, fungi, viruses (including bacteriophages) and archaea. These micro-
organisms are an integral part of the functional human unit. The human body hosts more than 
a trillion microbial cells and microbiome-associated genes outnumber human-coded genes 
100-fold.1 Humans and microbes have co-evolved over millions of years, and subsequently, 
the human immune system and the microbiome demonstrate complex interactions. The 
development of the microbiome is integral in shaping the immune response, while the immune 
system is required in order to maintain this large, and highly diverse set of microbes. Thus, a 
symbiotic interface has been established within the human body.2 
 
The advent of culture-independent new technologies such as highly-parallel DNA sequencing 
facilitated the beginning of the Human Microbiome (HM) Project, which signaled a phase shift 
from investigating single organisms in isolation, to investigating the whole microbial 
community. The HM project aimed to characterize the human microbiota and to analyze the 
role of micro-organisms in health and disease. The focus was on the bacteria found in five 
main body sites: oropharynx, skin, vagina, gut and nasal cavity. During the HM project, 
bacterial reference genomes were determined and an open-access database was established 
to allow collaborative efforts from laboratories worldwide.3,4 Collaboration between numerous 
laboratories has allowed the characterization of commensal bacterial species within a range 
of body systems. After initially concentrating on developing a reference set composed of a 
range of normal individuals, the role of microbial imbalance or dysbiosis in different disease 




Many modern molecular techniques exploit the 16S ribosomal RNA (rRNA) gene, a small and 
highly conserved locus contained within all bacterial genomes that allows easy identification 
of bacterial sequences, and a target for amplification and sequencing.6 Once sequenced, 
these can be referenced against the open-access databases to give genus and species level 
information. The next-generation sequencing technologies such as the 454 pyrosequencing 
and Illumina platforms allow whole communities to be characterised simultaneously and for a 
greatly reduced cost compared to previous sequencing technologies.7 The conserved 16S 
rRNA region is largely responsible for the large body of research now available focusing on 
bacteria, in comparison to the limited data regarding viruses and fungi present within human 
systems.  
 
Prior to the HM Project, culture-based techniques were used to investigate bacterial presence 
in the human body, which led to the assumption that the respiratory tract was a sterile site. 
Accordingly, the lungs were originally omitted from the list of priority sites for the HM project.8 
This appeared to disregard prior evidence from the 1970’s and 80’s suggesting that the lungs 
contained bacteria aspirated from the upper respiratory tract, identified using radiotracers in a 
group of healthy individuals.9,10 Subsequent to the initial efforts in mapping the human 
microbiome, research studies began to emerge that demonstrated that the lower respiratory 
tract is home to a diverse range of bacterial species with variations between health and 
disease states.11 In late 2009, the Lung HIV Microbiome Project was established with the aim 
“To characterize the microbiome of the lung and respiratory tract, and enhance understanding 
of the role of the lung microbiome in preserving health or causing disease and in the divergent 
effects observed in HIV-infected versus uninfected individuals.”12 Since then, numerous 
studies have characterised aspects of the bacterial microbiota in a range of acute and chronic 
respiratory conditions.  
 
The human microbiome is intricately involved in a range of normal and pathological processes 
during development, and throughout life. Traditionally, it was assumed that the microbiome 
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was established at birth, and its composition was dependent on route of delivery. The fetal gut 
microbiome demonstrates diverse communities within the first week of life, however a more 
mature equilibrium is not reached until approximately 3 years of age13. New published 
evidence indicates the presence of bacterial DNA in amniotic fluid and placental specimens, 
raising the possibility of microbiome exposure prior to birth.14,15 There are differences in the 
neonatal gut microbiome between full-term and pre-term infants. The major phyla in pre-term 
infants is Firmicutes compared with a dominance of Actinobacteria in full-term infants,16 which 
further suggests that microbiome seeding may occur during pregnancy and vary with 
gestational age. Additionally, breastfeeding in the early neonatal period appears to have 
significant effects on gut microbiota development. In a group of breastfed infants, virulence 
genes were increased within the gut microbiome, which correlated with up-regulation of 
immunity-related genes. Early exposure from the mother, both while in utero and in the first 
few weeks of life, plays an important role in the development of the microbiota in multiple 
organ systems.  
 
Establishment of the microbiome is crucial in immune development. The effect of early 
exposure to allergens was evaluated in a murine model, where exposure to house dust mite 
(HDM) in the early neonatal period lead to increased airway eosinophilia and airway hyper-
responsiveness. After establishment of lung microbiota and shifts from Firmicutes and 
Gammaproteobacteria towards a Bacteriodes predominance during the first two weeks after 
birth, a decreased response to aeroallergens was observed. An emergence of a Treg subset 
which required interaction with programmed death ligand 1 (PD-L1) appeared to be associated 
with this decreased allergen response.17 This demonstrates the importance of airway 
microbiota establishment in the development of atopic responses and possibly the later 
development of asthma. During childhood, diet, genetics and environmental exposures affect 
development of the microbiome, all of which play an important role in immune system 
maturation. Specifically, the oral microbiota, which in turn influences the lung microbiota, has 
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been shown to be influenced by external factors in the first 5 years of life, including 
breastfeeding, day care attendance and use of antibiotics.18,19  
 
The Human Respiratory Microbiome 
 
The respiratory microbiome includes all airway and lung-tissue associated microbes, and is 
more specifically defined as the lower respiratory tract beneath the larynx. Above this, the 
oropharyngeal and nasal-associated microbiota are separate to the lower respiratory tract 
microbiome and have received more attention previously due to ease of access.  
 
The majority of studies investigating the microbiome have focused on the gut due to the 
relatively large biomass present and the ease of sampling. Conversely, there are many 
challenges when attempting to characterize the microbiome of the respiratory tract. In 
particular, there are difficulties in obtaining samples from the distal airways due to the risk of 
upper airway contamination. The dominant methodologies employed in sampling the lower 
respiratory tract include bronchoalveolar lavage (BAL) obtained via bronchoscopy, and 
spontaneously expectorated or induced sputum. Sputum presents a less invasive method of 
sampling the lower respiratory tract but has an increased risk of oropharyngeal contamination 
due to passing directly through the upper respiratory tract. However, when used as a sampling 
technique in diseases such as cystic fibrosis (CF), bronchiectasis and chronic obstructive 
pulmonary disease (COPD), the biological signals detected have been significantly and 
meaningfully associated with multiple measures including severity of illness, airway 
inflammation, antibiotic use and risk of subsequent exacerbations.20-25 A further study found 
that expectorated sputum samples accurately represented the dominant microbes in the 
relatively homogenous respiratory tract of individuals with end-stage CF who had undergone 
lung transplantation, however sputum samples overrepresented the diversity and 
representation of atypical bacterial species.26 Bronchoscopy is a more invasive option, which 
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may have a lower rate of upper respiratory tract contamination. The bronchoscope is passed 
through either the oral or nasal cavity to sample the lungs, but once inserted, lavage is 
collected directly from distal airways without direct passage through the upper respiratory tract. 
A recent study27 using serial BAL analysis, demonstrated that sampling the lungs via 
bronchoscopy was not significantly confounded by the oral microbiome, consistent with 
previous serial bronchoscopy studies.28 The evidence from these studies supports the 
understanding that minimal contamination from the upper respiratory tract is present in lower 
respiratory tract samples when utilising bronchoscopic techniques. 
 
Sampling of the lower respiratory tract and lung tissues has indicated that there are 
approximately 10-100 bacterial cells per 1000 human cells within the lungs, 29 a greatly 
reduced biomass compared with other colonised body compartments. This may be due to 
lower levels of nutrient sources in the lungs supporting microbiota growth when compared with 
the gastrointestinal tract. Variable physiological conditions are present within the lungs which 
may also affect bacterial presence. These factors include pH, relative blood perfusion, relative 
alveolar ventilation, temperature, oxygen concentration, epithelial cell structure, deposition of 
inhaled particles, and number of inflammatory cells.30-32 These local selective pressures 
appear to play less of a role in healthy subjects. The greatest impact is seen in severe cases 
of chronic respiratory conditions where the lung microenvironment becomes maladapted due 
to remodelling of the airways and extra-cellular matrix.33,34  
 
Additionally, lung-associated biomass appears to be significantly lower than the upper 
respiratory tract biomass. Total bacterial signal level as measured by qPCR for 16S rRNA-
encoding genes in DNA, showed that the signal level was 100- 1000 fold lower in BAL samples 
when compared with an oral wash.27 A similar pattern was also observed with species 
richness, with a higher bacterial species richness in the oral cavity compared with both the 
lungs and the nasal cavity. This low concentration of microbiota within the lungs may be 
associated with the early understanding of lung sterility, but even after clear demonstration of 
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a resident lung microbiota using sequencing based approaches, the low biomass still presents 
further challenges in characterizing the burden and diversity of microbial species contained 
within the lower respiratory tract. 
 
Culture-based protocols characteristic of clinical microbiology laboratories are optimised to 
detect acute infections with respiratory pathogens in individuals and to distinguish their 
absence. They rely on sufficient microbial load and specific growth conditions to encourage 
growth of these bacterial species.35 These conditions selectively disadvantage the growth of 
anaerobes and bacteria which do not optimally flourish at 37°C, encompassing the majority of 
bacterial species which have now been determined to compose the healthy lung microbiota. 
Many of the species present within the healthy lung determined by culture-independent 
techniques, have now been grown in culture under modified conditions. The first study to utilize 
these culture-independent sequencing methodologies to characterize the microbiota in the 
lungs of healthy subjects showed that the lungs contain a distinct and diverse microbiome. 
Furthermore, the bacterial composition in the lungs of healthy controls was compared with 
asthmatic subjects, demonstrating early evidence of variations in the lung microbiota in 
patients with chronic respiratory diseases, specifically the relative enrichment of 
Proteobacteria.36  
 
Using culture independent techniques, it has since been determined that the most common 
bacterial phyla in the lower respiratory tract include Bacteroidetes, Firmicutes, and 
Proteobacteria. The most prominent genera present in healthy controls are Prevotella, 
Veillonella, and Streptococcus. Studies comparing concurrently collected upper and lower 
respiratory tract samples show that the microbial communities are distinct from each other, 
but there are similarities that prevail. This suggests that the traditional understanding of the 
respiratory tract as comprised of discrete, independent compartments is likely outdated. A 
more accurate representation of the respiratory tract is a single continuous, internally 
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heterogeneous ecosystem from the anterior nares through to the alveoli.27 Spatial 
heterogeneity of the microbial topography within this system occurs within different areas but 
there is constant movement of species between these areas.11 
 
This clear spatial heterogeneity within the different lobes of the lung37, and at different levels 
of the respiratory tract has been observed in chronic respiratory conditions. The turbulent act 
of coughing may play a role in homogenizing the microbial species within the lumen of the 
airways, thus decreasing spatial heterogeneity in healthy subjects.28,37 In disease states such 
as CF, where thick, sticky secretions prevent effective clearance of microbes through 
mucociliary and coughing mechanisms, spatial differences in microbes may be more 
commonly observed38. Lung disease alters the population dynamics and the lung terrain37, 
which translate into unique environmental conditions in each disease state which facilitate 
changes to the local microbial communities.  
 
The microbiota of the lungs is a balance between immigration of species, likely from 
microaspiration and direct movement into the lungs, elimination due to mucociliary 
mechanisms, cough and the innate and adaptive immune responses and selective pressures 
present within the lungs themselves. Previous studies have shown that microbiota from the 
oral cavity are constantly being introduced into the lower respiratory tract, often during sleep 
as a result of microaspiration9,10 and likely due to the direct mucosal extension between the 
oral cavity and the lungs. It has also been suggested that microaerosols generated in the oral 
cavity may be inhaled into the lungs and further contribute to the composition of the lung 
microbiome. The bacterial communities within healthy lungs demonstrate significant overlap 
with the bacterial species found in the oral cavity but not the nasal cavity. However, the relative 
abundance of bacterial phyla in healthy lungs appears to be significantly different from the oral 
bacterial community. Selective elimination of Prevotella species was observed in the lung, 27 
providing further evidence for the influence of selective pressures within the lower respiratory 




Elimination mechanisms are involved in clearance of microbial species from the respiratory 
tract. Mucociliary clearance and cough allow organisms to be mechanically removed from the 
lungs. Microbes are trapped within the mucus secreted from goblet cells and through the 
constant beating of cilia or coughing are moved up and out of the lower respiratory tract into 
the pharynx where they are either expectorated or swallowed. Host inflammatory cells and 
cytokines are involved in the immune response in the lungs leading to the clearance of 
potential pathogens. The composition of effector cells present within the airway appears to be 
associated with features of the microbiota.28 Therefore, a constant flux in the lung microbiota 
from introduction of oral microbes and elimination of species present within the lungs as well 
as selective pressures induced by the lung microenvironment, create a ‘steady state’ during 
health (Figure 1).27  
The Gut-Lung Axis 
The gut microbiome is modified in response to respiratory illness and chronic conditions while 
the lung microbiome also appears to be influenced by the gut microbiome. This complex 
interplay between these two body systems and the microbiomes contained within them is 
dubbed the ‘gut-lung axis’ and the vital cross-talk between their mucosal surfaces may have 
important implications for both health and disease. A study in children with CF demonstrates 
that the lung and gut microbiota likely develop simultaneously after birth. Furthermore, 
concordant fluctuations in bacterial species at both sites have been observed.39 Dietary intake 
also appears to influence changes in the lung microbiome, in addition to the gut.39,40 As 
mentioned earlier, the early development of the gut microbiota is important in the development 
of immune responses. The absence of a normal gut microbiota increases susceptibility to lung 
infection41, providing further evidence that the intestinal microbiome may influence the 




Dysbiosis in both the airway and intestinal microbiota has been observed in the presence of a 
range of respiratory diseases.42-44 Additionally, the course of some respiratory diseases has 
been shown to be modified by shifts in intestinal microbiota, such as the development of 
asthma and other atopic conditions.42,44 The hygiene hypothesis stipulates that reduction in 
environmental exposures, use of antibiotics and dietary changes can lead to disruptions of the 
gut microbiota, which in turn, leads to a decrease in immune tolerance. This resultant decrease 
in the Th1 immune response leads to a shift towards the propensity for allergic airway 
changes.45 In a murine model, early exposure to antibiotics caused a reduction in microbial 
load and diversity, which was strongly associated with the later development of allergic airway 
inflammation in adults who were exposed to aeroallergens.46 Conversely, the oral 
administration of probiotics including Lactobacillus species to children with CF led to a 
restoration of the intestinal microbiota to similar levels as healthy controls. The resultant 
microbiome composition has previously been shown to be associated with a reduction in the 
frequency of pulmonary exacerbations.43  
 
Acute bacterial and viral infections cause changes in the underlying microbiota. Chronic 
bacterial colonization with known pathogens such as Pseudomonas aeruginosa and 
Haemophilus influenzae in CF has been associated with distinct lung microbiomes, dominated 
by Prevotella and Flavobacterium in the case of P. aeruginosa and Neisseria when H. 
influenzae is present.47 Similarly, the microbiome may play a role in determining susceptibility 
to viral infection. The pneumococcal vaccine, and depletion of Streptococcus pneumoniae in 
an in vitro model has been associated with a 31% reduction in viral respiratory tract 
infections.48 Molyneaux et al showed that rhinovirus infection in healthy subjects has little 
effect on the underlying lung microbiota when measured in induced sputum samples. They 
did find, however, that in patients with COPD, rhinovirus infection led to an outgrowth of certain 
pathogenic bacteria, mainly those in the Proteobacteria phylum including Haemophilus 
influenzae.22 In a murine model, infection with influenza virus was shown to lead to changes 
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in the gut microbiome due to intestinal injury mediated by Th-17 cell-dependent 
inflammation.49 
 
Murine studies have shown that bacterial activation of Nod-like receptors in the gut led to 
increased reactive oxygen species in alveolar macrophages50 which are associated with 
effective bacterial clearance mechanisms in the lung. Peptidoglycan (a bacterial cell wall 
component) can translocate from the gut into the blood stream and the bone marrow to cause 
systemic and organ specific effects after systematic presentation to the host immune system 
via Nod1 receptors. This can lead to increased killing of Streptococcus pneumoniae and 
Staphylococcus aureus.51 Studies have shown that lipopolysaccharides (LPS), another 
bacterial product, can reduce viral infection rates suggesting that development of the gut 
microbiota may play an important role in susceptibility to respiratory viral infections. In vitro, 
pre-stimulation of human macrophages with LPS led to an 80% reduction in RSV and influenza 
infections52, demonstrating the complex interplay between bacterial and viral species.  
 
Inter-organ microbiome interactions are not only limited to the gut. Early establishment of a 
commensal nasopharyngeal microbiota appears to be protective of RSV-induced airway 
hyper-responsiveness. Mice were infected with RSV and subsequently treated with antibiotics 
which depleted Streptococcus viridans in the nasal passage associated with a strong immune 
response to the RSV infection with increased numbers of inflammatory lymphocytes, reduced 
Tregs and transforming growth factor-beta, and increased airway hyper-responsiveness.53 The 
interactions between the resident microbiomes within different organ systems are yet to be 
fully characterized, however for chronic respiratory disease sufferers, this area presents many 
possible future treatment avenues.  
 
Bacterial Studies  
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Pathological changes that occur in chronic respiratory conditions place selection pressures on 
the lung microbiome. Resultant shifts in growth patterns of specific bacterial populations are 
invoked by increased mucus production, changes in oxygen availability54 and temperature55 
in certain areas and an exacerbated inflammatory response leading to increased production 
of cytokines.56,57 Use of oxygen therapy, antibiotics and steroids in the treatment of these 
conditions may also impact the microbiome (Figure 1). As COPD, interstitial pulmonary fibrosis 
(IPF) and CF are the respiratory conditions for which lung transplantation is most commonly 
indicated, the microbiota associated variations observed in these diseases will be the focus of 
this chapter. All of these conditions demonstrate characteristic periods of ‘exacerbations’ or 
deterioration from the stable state. Emerging evidence indicates that these exacerbations may 




Multiple studies have investigated the lung microbiota of patients with COPD during stable 
periods when no evidence of lung infection could be observed. Several sample types including 
BAL, explanted lung tissue and expectorated sputum samples have been analyzed. These 
studies have revealed that the distal airways and alveoli in COPD patients contain a distinct 
microbiome which may prove relevant to the progression of the disease and the intermittent 
development of infectious exacerbations.11 Differences in the bacterial microbiome between 
individuals with COPD, non-COPD smokers and non-smoking controls have been observed. 
However, Erb-Downward et al did not demonstrate a distinct ‘COPD’ microbiome using 
sequencing techniques. Instead there was an extensive overlap in the bacterial communities 
between these three groups but decreased diversity of bacterial species in those with severe 
COPD.29,58 When the microbiome was characterised in lung tissue samples using PCR and 
terminal restriction fragment length polymorphism analysis, the microbiota seen in individuals 
with severe COPD differed from individuals with CF and mild COPD controls.29 An increase in 
microbiome diversity in COPD compared with healthy controls has also been demonstrated 
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using sequencing methods, however diversity did not seem to correlate with disease severity. 
Species clustering did occur, however, with use of inhaled therapy including both 
bronchodilators and corticosteriods.59 Spatial heterogeneity of bacterial species within the lung 
was markedly increased in patients with severe COPD.58 These shifts in the microbiota in 
COPD may be explained in part by the decreased surface area of the lung due to alveolar wall 
breakdown as the disease progresses, which leaves less available terrain for the distribution 
of the microbiota. This may also be responsible for the increased bacterial burden observed 
in severe destructive lung diseases.  
 
It has been postulated that changes in the microbiome may underlie exacerbations of COPD. 
A number of studies have compared the composition of the microbiome during stable periods 
with the composition during an exacerbation to determine if certain bacterial species are 
associated with worsening symptoms. Sethi et al compared the presence and load of the most 
common bacterial strains observed during an acute exacerbation and in the stable state of 
COPD. They found that change in bacterial load is unlikely to be the main mechanism involved 
in the occurrence of an exacerbation and suggested that host-pathogen interactions were 
more important.60 A study by Millares et al showed that colonization with Pseudomonas 
aeruginosa in severe COPD did not have significant effects on the biodiversity of the rest of 
the microbiome. Furthermore, during exacerbations, previous Pseudomonas colonization had 
little effect on the changes in microbes observed, compared to those who had never been 
colonized, including an increased abundance of Haemophilus, Streptococcus and Moraxella 
species.61 Furthermore, it has been observed that during an exacerbation, movement toward 
the Proteobacteria phylum, including detection of a range of non-typical COPD pathogens 
occurs. Treatment also appeared to be an important factor in microbiome shifts. Antibiotic 
treatment initially decreases Proteobacteria, but also induces overall microbiome suppression. 





Idiopathic Pulmonary Fibrosis   
There are few studies of the microbiome in the interstitial lung diseases. However, recent trials 
suggest that the microbiota may also have an important role in mediating the development of 
IPF. A randomized controlled trial showed a decrease in respiratory infections and an all-cause 
mortality benefit for patients receiving cotrimoxazole63, while the PANTHER trial demonstrated 
that immunosuppression led to increased mortality in patients with IPF.64 A limited number of 
studies have shown a role for the microbiota in predicting more severe disease and 
progression.65-68 It has also been shown that pneumolysin (pneumococcus-associated toxin) 
mediates fibrotic progression in animal models of alveolar epithelium injury.69 Therefore the 
presence of certain bacteria within the lung microbiota may predispose certain individuals to 
the development of IPF.  
Cystic Fibrosis 
It is generally accepted that pathogenic bacteria such as S.aureus and P.aeruginosa are 
commonly present within the lower airways of patients with CF and almost universally present 
by adolescence.70 CF was one of the notable exceptions to the previous understanding that 
the lungs were sterile. Hence, CF research has led the field in microbiome-related studies in 
chronic lung diseases.  
 
Microbial composition and diversity vary with disease progression. As patients develop more 
severe disease, bacterial community diversity has been shown to decrease significantly. 
However, in individuals with a mild lung disease phenotype, the bacterial community diversity 
remains stable over time. In both cases, microbial density remained steady. The most 
significant driver of a microbiome shift was antibiotic usage, however over time with increased 
usage, bacterial communities developed resistance to change.23,25 
 
Studies have suggested that treatment outcomes do not correlate with the susceptibility of 
strains of Pseudomonas aeruginosa to certain antibiotics. Two large trials have shown no 
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association between the clinical response to antibiotics during pulmonary exacerbations and 
in vitro bacterial susceptibility to the chosen antibiotics.71,72 This suggests that a single 
organism may not be responsible for causing an exacerbation. Instead, complex microbiome 
interactions may be of greater importance.  
 
Multiple studies in CF have shown that there is no change in bacterial burden or community 
diversity between samples taken during stable periods and at the time of exacerbations. It is 
instead suggested that an exacerbation occurs when there is an acute dysbiosis of the 
respiratory microbiome (acute shift in bacterial species) coupled with a disordered host 
immune response.25,73-75 Price et al showed that the lung microbiota in CF had a complex 
microbial composition, which appeared to be unique to each patient analysed. This 
microbiome demonstrated resilience to exacerbation and antibiotic treatment with persistence 
of microbial species observed at multiple time points.76 
 
Microbial interactions play an important role in CF exacerbation frequency and progression of 
the disease. Emerging research is examining the possibility of modifying the microbiome to 




Many host-specific and environmental factors have been shown to influence the human 
microbiota, however in this review, the focus will be on the impact of lung transplantation on 
respiratory microbiome dynamics and in contrast, how these variations in the lung microbiome 
affect transplant outcomes. Lung transplantation provides us with a unique opportunity to 
separate out host-specific, immune-related and extrinsic factors in shaping the microbiome 
after donor lungs have been transplanted into a new recipient. In effect, this is transplantation 




Lung transplantation is often the only viable option remaining for individuals with end-stage 
lung disease, providing patients with hope for an improved longevity and quality of life. 
However, compared with other solid organ transplantation, lung transplantation has the lowest 
long-term survival rates. Worldwide, the median survival time post bilateral lung transplant is 
7.4 years as reported in the International Society for Heart and Lung Transplantation (ISHLT) 
2017 Registry report compared with a median of 12.4 years for both living and deceased donor 
kidney transplantation.78  
Lung transplantation is associated with multiple opportunities for lower respiratory tract 
sampling with both surveillance and clinically indicated bronchoscopies. Some of the first lung 
microbiome studies incorporating longitudinal analysis were performed in the transplant 
cohort, due to the ability to conduct serial invasive sampling for surveillance of the allograft. 
Borewicz et al79 showed in a small cohort that the lung microbiome in transplant patients is 
not very stable in the early post-transplant period with less than 10% of species retained over 
the three time points. Another cohort of lung transplant recipients underwent longitudinal 
sampling of their lower respiratory tract for up to 12 months, showing that bacterial diversity 
increased during the first 9 months post-transplant. This likely reflects development of a new 
stable state in the donor lungs. After 9-12 months post lung transplant, bacterial diversity 
began to decrease.80 Finally, Willner and colleagues81 surveyed 16 patients who had been 
transplanted for CF and found dynamic changes in the lung microbiome over time which was 
heavily influenced by antibiotic use. These preliminary data indicate that there are important 
fluctuations in both microbiota burden and diversity, especially in the early transplant period. 
Some associations between bacterial diversity and negative outcomes81,82 have been 
suggested, however limited data at this point restrict conclusions. 
 
It has been previously thought that unanticipated donor transmission of infectious organisms 
is a rare, and dangerous event.83 Much work has focused on reducing the occurrence of 
transmission events, specifically of blood-borne viruses such as Human Immunodeficiency 
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Virus (HIV) and Hepatitis B (HBV) and C (HCV) viruses. However, emerging evidence shows 
that the microbiome is transplanted from the donor into the recipient at the time of lung 
transplantation and that the composition of the donor microbiome may have important 
implications for transplant outcomes. The post-transplant lung microbiome may also be 
modified through a range of factors. These include nosocomial acquisition of microbes from 
the ICU while intubated and from contact with other infected individuals while in hospital, 
transmission from the native lung in recipients who receive a single lung transplant, aspiration 
of gastric organisms due to the increased burden of gastro-esophageal reflux disease (GERD) 
in transplant recipients84 and the impact of the upper respiratory tract microbiota (Figure 2). 
Little research currently addresses the origin of the microbes that induce the longitudinal 
changes in the microbiome that have been previously described.79-81 Further research studies 
and a greater understanding are needed to characterize implications for clinical management.  
 
The vagus and other sympathetic nerves are transected at the hilum during lung 
transplantation causing loss of neural supply and complete denervation of the lungs in the 
early transplant period. This leads to decreased cough reflex, impaired ciliary beat frequency 
leading to impaired mucociliary clearance and implications for gastro-esophageal motility.85 
Reduction in mechanical clearance mechanisms such as cough and the mucociliary escalator 
have important implications in the ability of the recipient to clear inhaled pathogens and 
allergens and therefore reduces the rate of elimination of species which is important in 
maintaining the ‘steady state’ airway microbiota.86 Furthermore, recipients receive high level 
induction and maintenance immunosuppression87 which reduces the ability of the immune 
system to respond and clear microbial species, further impacting the elimination aspect in 
determining the microbial balance.  
 
The immigration of bacterial species into the lower respiratory tract is accelerated with 
gastroesophageal dysfunction and reflux, which lead to increased aspiration events. The 
incidence of GERD is significantly increased after lung transplantation,84 which has been 
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shown to impact the composition of the lower respiratory tract microbiota.32 Furthermore, the 
use of acid-suppression medications such as proton-pump inhibitors have been associated 
with an increased risk of overgrowth of acid-sensitive gastric flora such as Streptococcus and 
Staphylococcus, which were also found at higher concentrations in the lungs following reflux 
events, indicating the likely exchange of microflora between these two sites.88 These bacteria 
are often associated with symptomatic upper respiratory tract infections and pneumonia.89 
Laryngeal dysfunction and oral hygiene may also have an impact on lower respiratory tract 
microbiota due to increased pathogenic species in the oral cavity spreading to the airways, 
causing variations in the lung microbiome and through the increased risk of aspiration and 
inhalation events when there are alterations to the larynx.90,91 Furthermore, altered growth 
conditions within the lungs may have significant effects on microbiome dynamics with 
outgrowth of certain species and increased spatial heterogeneity within the lung field. These 
altered conditions may be caused by a number of factors including modifications to the airway 
terrain due to changes in ciliary function and mucus production, changes in regional growth 
conditions due to pneumocystis and general bacterial prophylaxis, and finally, effects of 
reperfusion after the transplant has occurred (Figure 2).37  
 
Mortality within the first-year post-transplant is associated with primary graft failure and acute 
rejection events. Within the first year of transplantation, up to 55% of recipients are treated for 
acute allograft rejection.92 However, there has been limited research in acute rejection 
compared with chronic rejection and bronchiolitis obliterans syndrome (BOS), but there is 
some evidence to suggest that both bacterial and viral infections, and possibly perturbations 
to the underlying microbiota, may have an important role in mediating early allograft 
dysfunction. Glanville et al showed that persistent Chlamydia pneumoniae infection is 
associated with early mortality and rejection events.93 Parainfluenza virus (PIV) infection also 
has a demonstrated association with the development of acute allograft dysfunction, with one 
study showing that 82% of patients with parainfluenza viral infection in their cohort also had 
evidence of acute allograft dysfunction. Furthermore, 32% of these PIV positive patients 
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developed bronchiolitis obliterans within 18 months follow up.94 Conversely, Ahya et al showed 
that detection of EBV DNA was not correlated with the development of acute allograft rejection. 
Instead, the authors suggested that increased viral load may be a surrogate marker of effective 
immunosuppression thus providing protective allograft effects.95 
 
The principal factor limiting long-term survival in lung transplant recipients is chronic lung 
allograft dysfunction (CLAD) mostly due to BOS. According to the ISHLT Registry Report, 50% 
of lung transplant recipients develop BOS within 5 years of transplant, while 76% of recipients 
develop BOS within 10 years.96 The primary pathological feature is bronchiolitis obliterans, a 
form of intraluminal airway fibrosis located mainly within the terminal bronchioles.97 It is now 
recognized that the causes of BOS are heterogeneous, and have differing clinical courses. 
Both viral and bacterial infections have been suggested to be risk factors for the development 
of BOS.98,99 New evidence emerging with the use of non-culture based techniques indicates 
that the underlying lung microbiome may play a greater role.8 Early studies investigating the 
respiratory microbiome post lung transplantation indicate that lung transplant recipients have 
variations in their lung microbiome compared with healthy controls100, and furthermore, that 
the microbiome changes over the post-transplant period79 as the lung microbiota becomes 
established within its new host and as an equilibrium is reached between the host immune 
response and immunosuppression levels. In these studies that have shown differences in 
transplant microbiome compared with healthy controls, one study has indicated increased 
bacterial burden in the BAL of lung transplant recipients79, while in others, decreased bacterial 
burden was observed in transplanted lungs.81,82,100 Some suggestions of decreased 
community diversity were seen. However, this appears to more commonly be the case in those 
with active respiratory symptoms and is not necessarily observed in asymptomatic controls.82 
Therefore, further information about the differences between symptomatic and asymptomatic 
transplant patients are required including elucidating how these may correlate with both 




A number of studies have investigated the relationship between the presence of specific 
members of the microbiome and the risk of BOS. This relationship was first demonstrated 
using traditional culture-based techniques and serum antibody detection. More recently the 
advent of metagenomics techniques has allowed the dynamics of the greater lung microbiome 
to be examined in more detail. Some bacterial species, such as Pseudomonas appear to play 
a greater role in mediating the development of BOS. Multiple culture based studies have 
consistently shown that airway colonization with P. aeruginosa is predictive of subsequent 
development of chronic rejection.”99,101-103 However, one study has shown a negative 
correlation between presence of Pseudomonas spp. and development of BOS.81 In those 
studies where a positive relationship between Pseudomonas colonization, and development 
of BOS was seen, de novo colonization post-transplant rather than persistence of pre-
transplant Pseudomonas colonization had an increased likelihood of BOS development.81,103  
 
Patients with suppurative lung disease, including CF, who had chronic colonization prior to 
transplant are at a greater risk of re-infecting the allograft with persistent bacterial species 
from the upper airway and the sinuses (Figure 2). Vital et al attempted to mitigate this risk by 
performing endoscopic frontal-spheno-ethmoidectomy procedures immediately post-
transplant and using multiple Pseudomonas-active antibiotics. Despite this treatment, 65% of 
patients had persistent colonization post-transplantation. This study also demonstrated 
greater BOS-free survival in those patients who did not demonstrate detection of 
Pseudomonas.104 Dickson et al identified two distinct Pseudomonas species which were both 
prominent in the lung microbiome samples of lung transplant recipients, but were associated 
with distinct clinical phenotypes. P. aeruginosa, when detected, is usually seen in high 
abundance and is accompanied by acute clinical infection, whereas P. fluorescens is usually 
detected at a moderate abundance and is rarely correlated with development of acute 
symptomatic infection.82 If the bacteria are only identified at the family level, the distinction 
between these species may be missed. P. fluorescens has been shown to be rarely detected 
using culture-based methodologies, thus the authors suggest this may account for the lack of 
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correlation between detection of Pseudomonas and development of BOS seen in the study by 
Willner et al, who utilised culture-independent techniques.81 Therefore, characterization of the 
microbiome and subsequent monitoring may provide further information on risk of BOS. It also 
highlights the future possibility of modifying the microbiome in attempts to reduce the 
development of BOS.  
 
The increased access to culture independent techniques has played an important part in 
defining the role of the respiratory microbiome in lung transplantation. Variations in the lung 
microbiome post-transplant appear to modify the risk of both acute and chronic rejection 
events. Lung transplantation provides us with a unique scenario in which to investigate the 
lung microbiome and the changes that may occur in response to a new host, surgery-related 
damage and donor-transmission events. The substantial follow-up opportunities presented 
have allowed the lower respiratory tract microbiome to be monitored longitudinally and for the 
dynamics and shift of microbial species to begin to be elucidated.  
 
Fungal Studies  
Compared with the bacterial component of the lung microbiome, the fungal component termed 
the ‘mycobiome’ represents a largely understudied area with fewer than 10 published papers 
describing the fungal composition of the microbiome using next generation sequencing 
techniques (NGS). Despite the limited data present in this area, there appears to be many 
parallels between the fungal and bacterial components of the microbiome including the 
understanding that fungal species are present during health, and that there is significant intra-
subject variability in the diversity of species detected.105 Limited studies have compared fungal 
and bacterial species in disease states with healthy controls. The most common fungal genera 
identified in healthy lung samples were Cladosporium, Eurotium, Penicillium, Aspergillus, 
Candida, and Pneumocystis.100,106 Similarly to the bacterial component, a large range of fungal 
species have been found in lung samples since the use of NGS, which are not detectable by 
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culture. Up to 82% of the fungal species detected in sputum samples by sequencing were 
unable to be cultured. Furthermore, in this group of 55 CF patients, only 27% were found to 
be positive for fungus when culture-based methods were used, compared with 90% of the 
cohort being positive by sequencing.107 
 
The lung mycobiome has been investigated in CF and COPD, with decreases in fungal 
diversity being observed. Furthermore, decreased fungal diversity has been associated with 
lower lung function. It has been suggested that the decreased diversity may be due to out-
growth of a single species, or the loss of rare species as part of overall decreased fungal 
abundance.    In CF, it has been shown that the highest species richness is observed in those 
with the lowest disease severity scores.106 Similarly to the observations from the bacterial 
component of the microbiome, fungal communities also appear to remain stable through 
antimicrobial therapy and exacerbations.108,109 There are very limited data regarding the 
mycobiome in COPD, however two studies have shown Aspergillus110 and Pneumocystis111 to 
be highly represented species within BAL samples from patients with COPD. How these 
interact with other fungal species, and other bacterial members of the microbiome is yet to be 
elucidated. 
 
Many aspects impact the microbiome in transplant, including donor transmission, structural 
changes within the lungs and immunosuppression. However, there is still limited information 
regarding how these factors impact the mycobiome. The fungal aspect of the microbiome has 
been characterised in a small set of lung transplant patients showing that in general, there is 
decreased fungal abundance and diversity compared with healthy controls. Charlson et al 
characterised the lung mycobiome in 21 patients following lung transplantation, and found that 
in many cases, it was largely dominated by Candida species which were also found in the 
oropharyngeal wash of these subjects. In two individuals, high levels of Aspergillus were 
detected, however these were largely absent in the oropharyngeal wash samples. 
Furthermore, Cryptococcus was observed in the BAL samples of 6 patients at relatively low 
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abundance.100 Indication for transplant also appears to have an effect. Individuals transplanted 
for CF showed the lowest species richness.100 
 
Certain members of the mycobiome may be associated with negative outcomes post-
transplant. Colonization with Aspergillus has been shown to be strongly associated with 
development of BOS and increased BOS-related mortality using Cox-regression analyses.112 
Willner et al demonstrated that Aspergillus species were decreased in transplant patients who 
had Pseudomonas-dominated microbiomes, which was shown to be negatively correlated with 
the development of BOS.81 Therefore, further characterization of the mycobiome is necessary 
to determine the contribution of members to negative outcomes post lung transplantation. This 
may contribute to long-term treatment strategies in microbiome manipulation as a way of 
mitigating the development and progression of BOS.  
 
Virome Studies  
There are limited data in the area of the virome due to the inherent limitations in isolating and 
defining this part of the microbiome. In the lungs, the bacterial biomass is reduced compared 
with other compartments such as the intestine and the oral cavity. The amount of viral genomic 
material is even lower. Isolating viral nucleic acids without the use of a conserved sequence 
such as 16S in bacteria or ITS region for fungi, and effectively depleting both human and 
bacterial genomic material presents many challenges and may account for the lag in our 
knowledge of the viral component of the microbiome. 
 
The first studies in the area of the lung virome were in patients with CF, paralleling the early 
studies of the bacterial component of the microbiome. Bacteriophage communities in a small 
cohort of individuals with CF were compared with healthy controls, to demonstrate that there 
appears to be a core set of bacteriophages found in the healthy lung and an additional core 
set of phages found in individuals with CF which correspond to concurrent pathogenic bacterial 
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species. In CF, the lung bacteriophage community appears to be driven by airway pathology 
and the persistence of certain bacteria.113 The same group conducted a small case series 
evaluating spatial heterogeneity within CF lungs. A large range of DNA viruses and 
bacteriophages were observed within the lungs of individuals with end-stage lung disease, 
with clear heterogeneity in the presence of viruses within different lobes of the lungs.38 
Since then, a handful of studies have largely characterized the virome in individuals with acute 
viral infections. In this case, there is an overwhelming abundance of the causative organism 
which is often concurrently detected using PCR methods. However, a range of other viral 
species including torque teno viruses, herpes viruses and community acquired respiratory 
viruses such as picornavirus and adenovirus have been characterised in these samples.114,115 
Furthermore, a study characterizing the respiratory virome in febrile and afebrile children has 
provided evidence to show that a resident lung virome is likely established in healthy children 
within the first two years of life which may also impact the development of the immune 
system.116 
The human respiratory virome has been investigated in lung transplantation. Young et al have 
characterized the DNA virus profile in the oropharyngeal washes and BAL samples post-
transplant.117 A range of DNA viruses were detected using sequencing, including herpes 
viruses, human papillomavirus and bacteriophages. Anelloviruses, including torque teno virus, 
dominated these samples accounting for over 68% of reads. These anelloviruses were further 
quantified using real time qPCR. Transplant patients were shown to have significantly greater 
viral loads in both the oropharyngeal wash and BAL samples compared to healthy controls.117 
A further study explored the role of torque teno virus in lung transplant recipients in the peri-
operative period. Torque teno virus was shown to increase in the immediate post-operative 
period, however the magnitude of viral load increase was shown to be associated with 
development of primary graft dysfunction.118 Therefore, monitoring changes in the virome may, 
in the future, assist in determining risk profiles for graft injury and adequate levels of 




There is some evidence to suggest that viral infections are associated with the development 
of BOS. Garantziotis et al showed a relationship between infection with influenza and 
subsequent decline in lung function associated with early graft dysfunction and / or BOS.119 
A further study has indicated that the one-year incidence of BOS is significantly increased 
(25%) in patients who have had a respiratory virus detected by PCR compared with virus-
negative patients (9%). However, detection of a respiratory virus in patients who already had 
diagnosed BOS had no impact on progression.120 This was further evidenced by a 
retrospective 5-year cohort study on lung transplant patients, where detection of a lower 
respiratory tract viral infection was significantly correlated with development of BOS and BOS-
related mortality.121 A further study that compared patients with symptomatic viral infection 
with asymptomatic controls, demonstrated PCR detected virus in the symptomatic group 
which was associated with both acute rejection events and progression to BOS.122 
 
The herpes group viruses have been studied extensively as a quasi-resident species within 
the lungs of transplant recipients. Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) as 
well as Human Herpesvirus Type 6 (HHV-6), in particular, have received attention but data 
regarding their relationship to allograft dysfunction are somewhat confounded by the efficacy 
of prophylactic use of specific antiviral therapies.123 Some relationships are clear. An EBV 
naïve recipient of an EBV positive lung allograft has the highest risk of developing post-
transplant lymphoproliferative disease (PTLD) (50% in some series) which carries a high 
mortality rate. This has been somewhat ameliorated of recent times by the selective use of 
anti-CD20 monoclonal antibody therapy to target EBV driven B-cell clonal expansion as an 
adjunct to reduction in immune suppression which, of itself, was commonly associated with 
the development of acute cellular rejection and graft dysfunction. This relationship between 
the risk of PTLD and EBV viral load has led some units to pursue a policy of peripheral load 
monitoring in blood using a quantitative EBV PCR with the intention of reducing immune 
suppression pre-emptively if EBV load increases, to circumvent the risk of PTLD.124 
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Conversely an absent EBV load raises the question of acute rejection risk. The oncogenic 
potential of EBV, Kaposi's sarcoma herpesvirus (KSHV), and human T-lymphotropic virus type 
1 (HTLV-1) has been confirmed by high-throughput RNA sequencing data from 50 common 
lymphoma cell culture models from the Cancer Cell Line Encyclopedia project.125 The role of 
HHV-6 in the pathogenesis of organizing pneumonia, a not uncommon finding on 
transbronchial biopsy deserves further study.123 Repeated EBV DNA detection in blood, 
possibly reflecting chronic EBV replication, has been associated with the development of 
BOS.126 
CMV can cause fulminant pneumonia and death, which since the development of effective 
treatment modalities127 is now rare, except for drug resistant strains, an ever-present risk of 
the use of widespread prophylaxis.128 A largely intracellular virus, CMV can be detected in 
bronchoalveolar lavage fluid and analysis of paired samples suggests detection of CMV DNA 
in BAL fluid reflects virus replication in the lung rather than oropharyngeal contamination.129 
Whether BAL load monitoring assists in the determination of a therapeutic decision is 
debatable versus a qualitative assessment. However, peripheral load monitoring in blood 
using a quantitative PCR is the gold standard for initiation of therapy versus prophylaxis. CMV 
naïve recipients of a positive donor graft hold the highest risk of CMV pneumonia, therefore 
there exists some evidence for ongoing prophylaxis.130 
 
To date, there are very limited studies characterizing the human virome, and none in the areas 
of COPD or IPF. Further research may help to elucidate the changes in the resident virome 
between different disease states, and how these impact progression. Early studies in lung 
transplantation show distinct differences in the respiratory virome composition and diversity 
between lung transplant recipients and healthy controls. However, the detection of causative 
viral organisms in symptomatic individuals has been associated with negative transplant 
outcomes. The presence of certain viral species, and their viral load may help to guide 
treatment strategies and modifications to the respiratory virome may improve outcomes for 
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patients in the future (Figure 3). In the majority of lung virome studies published, sequencing 
has focused on the DNA virus community due to the inherent limitations of working with RNA 
viruses which are much more prone to degradation. Little is known about the role of RNA 
viruses in both healthy individuals and in disease states, including after transplantation. 
Further studies, particularly those with a prospective longitudinal design, are needed to 
describe the large collection of viruses detected by NGS which remain unnamed and 
uncharacterized and to determine their role within the greater microbiome in both health and 
disease.  
 
Summary and Conclusions 
In a very real sense, our understanding of the component parts of the microbiome and, in 
particular, the human respiratory microbiome is just beginning. New tools, including next 
generation sequencing are now available to assist in the exploration of this exciting field of 
knowledge, however much work remains. Essentially, we need to define the constituents of 
the human respiratory microbiome in health and in disease states. Furthermore, we need to 
develop an understanding of the range of normal throughout different phases of life and 
between different communities. In the human respiratory virome, in particular, it is vital to 
appreciate the concept of resident species such as anelloviruses and the impact of transient 
species such as community acquired respiratory viruses to underpin future research given the 
ubiquitous nature of the latter. Mapping the spatial architecture within the lung could also prove 
critical in localizing pathology to lung regions and providing potential targeted therapeutic 
options. Similarly, the ability to detect pathological alterations in the respiratory microbiome 
will depend on a deep understanding of the dynamics and inter-relationships between 
bacteria, viruses, fungi and archaea. The study of these relationships will perhaps become a 
field unto itself. To date, there are little data in this area as a silo mentality has prevailed which 
has allowed a focus on one component at a time, perhaps reflecting individual interests and 
experience, as well as the limits of technology available, not to mention financial constraints. 
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The challenge, therefore, for funding bodies especially, is to see and appreciate the whole, 
and not just the component parts. Only then, will the workings of the integrated machine 
become clear and our contemporary knowledge, which has been beset by false premises of 
microbial sterility of the lung, be cast aside to permit a revised vision of the complex microbial 
basis of this precious organ that allows us to breathe. Transplanting the human respiratory 
microbiome, as perforce is integral to lung transplantation, is a bold endeavor replete with its 
own special challenges where early exploratory evidence based on serial monitoring is 
showing promise of recognizing causes and outcomes of dysbiosis related to immune 
suppression. Whether real time analysis will permit therapeutic adjustments to facilitate better 
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Figure 1: Dynamics of the Human Respiratory Microbiome 
The human respiratory microbiome comprises all organisms that live in or on the human lung 
and respiratory tract including bacteria, fungi, archaea, viruses and bacteriophages. 
Numerous forces combine to create a dynamic situation such that the net result represents 
the balance between acquisition, elimination and local defense measures designed to 
maintain an equilibrium between resident and transient species. 
Figure 2: Dysbiosis of the Lung Microbiome after Lung Transplantation 
After lung transplantation, the healthy lung equilibrium between resident and transient species 
may be challenged by the donor microbiome transplanted within the new lungs which may be 
qualitatively and quantitatively different from the microbiome of the explanted native lungs. 
Other external events can also lead to dysbiosis including community acquired respiratory 
virus infection, the ex-vivo stage of lung procurement and the impact of immune suppression. 
Figure 3: Dynamics of the Human Respiratory Virome after Lung Transplantation 
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This concept diagram demonstrates a potential temporal relationship between resident viral 
species within the lung and transient species. Specific events lead to blooms of resident 
species such as the ex-vivo stage of lung procurement and heightened immune suppression. 
It is likely but not proven that acute community acquired respiratory virus (CARV) infection 
may suppress resident species temporarily while the impact of the development of chronic 
lung allograft dysfunction (CLAD) may depend on phenotype and also on therapies employed. 
 
